María Victoria
Mateos Manteca
Publicaciones (516) Publicaciones de María Victoria Mateos Manteca
2024
-
A research center’s experience of T-cell–redirecting therapies in triple-class refractory multiple myeloma
Blood Advances, Vol. 8, Núm. 13, pp. 3478-3487
-
ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study
Haematologica, Vol. 109, Núm. 3, pp. 867-876
-
An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma
European Journal of Haematology
-
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
New England Journal of Medicine, Vol. 391, Núm. 5, pp. 393-407
-
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
The New England journal of medicine, Vol. 391, Núm. 5, pp. 408-421
-
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Haematologica
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 4, pp. 224-231.e2
-
Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715
-
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology
-
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Blood Advances, Vol. 8, Núm. 2, pp. 388-398
-
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Haematologica, Vol. 109, Núm. 3, pp. 895-905
-
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study
Haematologica
-
Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed/refractory multiple myeloma: Extended follow-up subgroup analysis of the BOSTON trial
European Journal of Haematology, Vol. 113, Núm. 2, pp. 242-252
-
Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study
Cancer, Vol. 130, Núm. 6, pp. 886-900
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Mass Spectrometry as Alternative Method to Identify and Monitor Non-Secretory Progressive Disease in Patients with Multiple Myeloma
Biomedicines, Vol. 12, Núm. 6
-
Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies
The Lancet Haematology, Vol. 11, Núm. 9, pp. e693-e707